Haemonetics Co. (NYSE:HAE) Short Interest Down 6.4% in March

Haemonetics Co. (NYSE:HAE) was the target of a large decrease in short interest in the month of March. As of March 31st, there was short interest totalling 2,040,000 shares, a decrease of 6.4% from the March 15th total of 2,180,000 shares. Currently, 4.1% of the company’s shares are short sold. Based on an average daily volume of 455,600 shares, the days-to-cover ratio is presently 4.5 days.

Analyst Ratings Changes

A number of analysts have weighed in on HAE shares. TheStreet downgraded shares of Haemonetics from a “b-” rating to a “c+” rating in a research report on Thursday, February 29th. Barrington Research reissued an “outperform” rating and set a $105.00 target price on shares of Haemonetics in a research report on Friday. Finally, StockNews.com downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd.

Institutional Investors Weigh In On Haemonetics

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in shares of Haemonetics by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 5,380,858 shares of the medical instruments supplier’s stock worth $482,017,000 after purchasing an additional 27,146 shares during the period. Kingdon Capital Management L.L.C. bought a new stake in shares of Haemonetics during the 3rd quarter worth $9,952,000. Lazard Asset Management LLC raised its stake in shares of Haemonetics by 114.2% during the 3rd quarter. Lazard Asset Management LLC now owns 38,538 shares of the medical instruments supplier’s stock worth $3,452,000 after purchasing an additional 20,550 shares during the period. Los Angeles Capital Management LLC raised its stake in shares of Haemonetics by 1.1% during the 3rd quarter. Los Angeles Capital Management LLC now owns 53,058 shares of the medical instruments supplier’s stock worth $4,753,000 after purchasing an additional 586 shares during the period. Finally, Eagle Asset Management Inc. raised its stake in shares of Haemonetics by 2.6% during the 3rd quarter. Eagle Asset Management Inc. now owns 268,643 shares of the medical instruments supplier’s stock worth $24,065,000 after purchasing an additional 6,828 shares during the period. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Stock Down 0.8 %

NYSE:HAE traded down $0.71 during trading hours on Tuesday, hitting $84.17. 273,091 shares of the company traded hands, compared to its average volume of 444,185. The company has a quick ratio of 1.76, a current ratio of 2.92 and a debt-to-equity ratio of 0.91. The firm’s 50-day simple moving average is $78.42 and its 200-day simple moving average is $82.80. Haemonetics has a one year low of $70.74 and a one year high of $95.26. The company has a market cap of $4.27 billion, a PE ratio of 34.39, a PEG ratio of 2.01 and a beta of 0.36.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share for the quarter, beating the consensus estimate of $0.94 by $0.10. The business had revenue of $336.20 million for the quarter, compared to analysts’ expectations of $320.84 million. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The business’s revenue was up 10.1% on a year-over-year basis. During the same period last year, the business earned $0.85 EPS. Equities analysts predict that Haemonetics will post 3.95 earnings per share for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.